These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36344514)

  • 1. The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia.
    Xu H; Yang F
    Transl Psychiatry; 2022 Nov; 12(1):464. PubMed ID: 36344514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dopamine in schizophrenia and Parkinson's disease.
    Birtwistle J; Baldwin D
    Br J Nurs; 1998 Jul 23-Aug 12; 7(14):832-4, 836, 838-41. PubMed ID: 9849144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.
    Acharya S; Kim KM
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine and the regulation of cognition and attention.
    Nieoullon A
    Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.
    Ben-Shachar D
    J Neural Transm (Vienna); 2009 Nov; 116(11):1383-96. PubMed ID: 19784753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic (DA) systems: their role in pathological neurobehavioral symptoms.
    Majovski LV; Jacques S; Hartz G; Fogwell LA
    Neurosurgery; 1981 Dec; 9(6):751-7. PubMed ID: 6459537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease.
    Weickert TW; Mattay VS; Das S; Bigelow LB; Apud JA; Egan MF; Weinberger DR; Goldberg TE
    Schizophr Res; 2013 Sep; 149(1-3):162-6. PubMed ID: 23830543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade and reversal of swimming-induced paralysis in C. elegans by the antipsychotic and D2-type dopamine receptor antagonist azaperone.
    Refai O; Blakely RD
    Neurochem Int; 2019 Feb; 123():59-68. PubMed ID: 29800604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
    Zhou ZD; Xie SP; Saw WT; Ho PGH; Wang H; Lei Z; Yi Z; Tan EK
    Cells; 2019 Aug; 8(8):. PubMed ID: 31426448
    [No Abstract]   [Full Text] [Related]  

  • 13. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.
    Remington G; Agid O; Foussias G
    Expert Rev Neurother; 2011 Apr; 11(4):589-607. PubMed ID: 21469931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
    Loo H; Cuche H; Sechter D
    Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
    Tsai SJ
    Med Hypotheses; 2004; 63(6):1047-50. PubMed ID: 15504573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia.
    Devroye C; Cathala A; Haddjeri N; Rovera R; Vallée M; Drago F; Piazza PV; Spampinato U
    Neuropharmacology; 2016 Oct; 109():59-68. PubMed ID: 27260325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurodevelopmental role of dopaminergic signaling in neurological disorders.
    Cai Y; Xing L; Yang T; Chai R; Wang J; Bao J; Shen W; Ding S; Chen G
    Neurosci Lett; 2021 Jan; 741():135540. PubMed ID: 33278505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease.
    Hastings TG
    J Bioenerg Biomembr; 2009 Dec; 41(6):469-72. PubMed ID: 19967436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
    Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
    Elife; 2021 Sep; 10():. PubMed ID: 34550070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target.
    Ben-Shachar D
    Schizophr Res; 2017 Sep; 187():3-10. PubMed ID: 27802911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.